Ipsen: positive data for lanreotide
(CercleFinance.com) - Ipsen has announced the publication of the first data on safety and efficacy of the CLARINET FORTE study, which will be the subject of an oral mini-presentation at the European Society for Medical Oncology (ESMO) Congress 2020 (from 19 to 21 September).
This Phase II study evaluated Somatuline Autogel (lanreotide) at a higher frequency in patients with pancreas or digestive tube TNE who had shown disease progression over the last two years.
According to the pharmaceutical laboratory, data revealed an increase in the progression-free survival rate and an encouraging disease control rate (DCR) for both types of tumours, without new safety signals.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
This Phase II study evaluated Somatuline Autogel (lanreotide) at a higher frequency in patients with pancreas or digestive tube TNE who had shown disease progression over the last two years.
According to the pharmaceutical laboratory, data revealed an increase in the progression-free survival rate and an encouraging disease control rate (DCR) for both types of tumours, without new safety signals.
Copyright (c) 2020 CercleFinance.com. All rights reserved.